Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Trial ID or NCT#
NCT05395624
Status
RECRUITING
Purpose
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
Official Title
A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers
Eligibility Criteria
Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Investigator(s)
Kathleen Poston, MD, MS
Neurologist,
Movement disorders specialist
Edward F. and Irene Thiele Pimley Professor of Neurology and the Neurological Sciences and Professor, by courtesy, of Neurosurgery
Kip E. Guja, MD PhD
Clinical Instructor, Radiology - Rad/Nuclear Medicine
Irina Skylar-Scott
General neurologist,
Memory disorders specialist
Clinical Assistant Professor, Neurology & Neurological Sciences
Jeffrey Dunn, MD
Multiple sclerosis specialist,
Neurologist
Clinical Professor, Neurology & Neurological Sciences
Contact us to find out if this trial is right for you.
Contact
Caroline Huang
(650) 723-0341
View on ClinicalTrials.gov
